Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FLUFF RELEASE. Waiting on update from Honda
As you will read from today's PR LASE is going to need a much larger payroll.
Laser Photonics Welcomes New Outside Sales Director To Propel Laser Material Processing Market Penetration
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (NASDAQ: LASE) (LPC), a leading global developer of laser systems for cleaning and other material processing applications, announced today that it has appointed Robert Hoffman as its new Outside Sales Director as part of its long-term growth and diversification strategy.
Prior to joining Laser Photonics, Hoffman served as the Southeast Regional Sales Manager for Keyence, a leading provider of factory automation solutions, including sensors, measuring systems, laser markers, microscopes, and machine vision systems. He also held the role of Project Manager at Easy Imex, assisting businesses from Australia, the United Kingdom, the United States, and Europe in importing products from overseas. Earlier in his career, he managed logistics accounts at Total Quality Logistics, one of the nation's largest freight brokerage firms, and worked as a Quality Assurance Specialist for Bluegreen Vacations, focusing on legal and financial transactions.
This strategic appointment aligns with LPC's goal of driving revenue growth and fostering client relationships in rapidly expanding technical sectors. Hoffman's extensive sales expertise in factory automation and various manufacturing sectors makes him an ideal fit for LPC's ambitious expansion plans.
"Robert's experience will be crucial in implementing the innovative sales processes needed for our growth," said Wayne Tupuola, CEO of LPC. "He brings a wealth of expertise and achievement in sales and sales management, particularly in manufacturing centers and the high-growth automation field. As we continue to invest in our sales organization over the next year, Robert's leadership and understanding of LPC's target customers will be instrumental in reducing sales cycle times and streamlining processes necessary for our growth."
Hoffman added, "I am thrilled to join Laser Photonics on its journey to capture an even larger share of the market. One of my immediate goals is to enable our sales staff to conduct more demonstrations and part testing at customer facilities. Onsite sample testing will not only speed up the sales cycles but also demonstrate our commitment to providing service and exceptional product performance. I am dedicated to helping establish LPC as a key player in the material processing space."
Hoffman received his B.S. in Economics from Florida State University. He brings more than 10 years of sales leadership experience in business-to-business (B2B) sales, strategic planning, technical sales and operations, account management, inventory planning, financial analysis and forecasting, logistics planning and quality assurance.
I told that dog over 1 month ago to call a plumber. He got upset with at that statement so Roto-Rooter never showed
Here is your News. Better late than never.
SunHydrogen Joins Texas Hydrogen Alliance to Support the Growth of the Hydrogen Economy
CORALVILLE, IA – September 24, 2024 – SunHydrogen, Inc. (OTCQB: HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today announced that it has joined the Texas Hydrogen Alliance, a coalition of industry leaders dedicated to advancing the hydrogen economy in Texas.
Founded in 2021, the Texas Hydrogen Alliance is a 501(c)(6) non-profit trade organization that brings together policymakers, regulators, industry leaders and innovators to advocate for policies that expedite hydrogen adoption, promote low-carbon hydrogen production, and develop robust infrastructure for storage and distribution. The Alliance seeks not only to strengthen Texas' position as the energy capital of the world, but also to create new opportunities for economic growth and innovation in the hydrogen sector.
“We believe our business plan is very well-aligned with current plans to expand the hydrogen economy in Texas, including the creation of a hydrogen trucking corridor throughout the state,” said SunHydrogen’s CEO Tim Young.
The innovative solar hydrogen panels SunHydrogen is developing use abundant and low-cost materials, require no external power other than sunlight, and are designed with scalability in mind. The Company intends to install its green hydrogen panel arrays at and near roadside refueling sites along major trucking routes with abundant land and sun, lowering the high costs and hydrogen losses associated with typical long-distance transport.
In January 2024, Texas received a $70 million grant from the Federal Highway Administration supporting the creation of a hydrogen trucking corridor for medium and heavy-duty trucks. The funding will go toward the construction of up to five stations across Dallas-Fort Worth, Houston, Austin and San Antonio, with the eventual goal of building a corridor between Texas and Southern California.
Additionally, Texas is the site of the HyVelocity Hydrogen Hub, one of seven regional clean hydrogen hubs selected by the U.S. Department of Energy to receive up to $1.2 billion in funding. HyVelocity Hub participants Air Liquide, Chevron, ExxonMobil and Sempra Infrastructure are also part of the Texas Hydrogen Alliance.
“Our membership in the Alliance brings tremendous opportunity to make inroads into the Texas hydrogen landscape and beyond,” Mr. Young said. “SunHydrogen greatly looks forward to engaging with prestigious industry leaders and fellow innovators.”
About SunHydrogen, Inc.
SunHydrogen is developing breakthrough technologies to make, store and use green hydrogen in a market that Goldman Sachs estimates to be worth $12 trillion by 2050. Our patented SunHydrogen Panel technology, currently in development, uses sunlight and any source of water to produce low-cost green hydrogen. Like solar panels that produce electricity, our SunHydrogen Panels will produce green hydrogen. Our vision is to become a major technology supplier in the new hydrogen economy. By developing, acquiring and partnering with other critical technologies, we intend to enable a future of emission-free hydrogen production for all industrial applications such as fertilizer and petroleum refining as well as fuel cell applications for mobility and data centers. To learn more about SunHydrogen, please visit our
PUMP IT LOL
On the maturity date of the Bridge Financing, the Loan Parties are obligated to make a payment equal to all unpaid principal and accrued interest. The Loan and Security Agreement also provides that all present and future indebtedness and the obligations of the Borrower to Madryn shall be secured by a priority security interest in all real and personal property collateral of the Loan Parties.
The initial drawdown under the Loan and Security Agreement occurred on April 23, 2024, when the Lenders agreed to provide the Borrower with bridge financing in the form of a term loan in the principal amount of $2,237,906.85.
The second drawdown under the Loan and Security Agreement occurred on July 26, 2024, when the Lenders agreed to provide the Borrower with a subsequent drawdown under the Loan and Security Agreement in the principal amount of $1,000,000.
On September 11, 2024, the Lenders agreed to provide the Borrower with a subsequent drawdown under the Loan and Security Agreement in the principal amount of $1,000,000 (the “September Drawdown). The September Drawdown was fully funded on September 11, 2024. The Company expects to use the proceeds of the September Drawdown, after payment of transaction expenses, for general working capital purposes.
I just let the last of my shares go. She is obnoxiously overbought and the Company needs $$$$ so will wait for a PP. These shares will be on their way down once that happens
$LASE ripping to all new heights! Now $14.90
$LASE hits yet another 52-week high of $11.30
Of course,that is just some of the things they did. https://stock.adobe.com/search?k=%22puma+punku%22
The ancient advanced civilizations before the great flood had tech similar to this!😆
There is your $10 bucks along with a fresh 52-week high😆
Laser Photonics Releases Shareholder Letter on Growth and Strategic Plans
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global developer of industrial laser systems for cleaning and other material processing applications, has released a shareholder letter.
Dear Laser Photonics Shareholders,
As we’re about to end the third quarter and transition into the fourth, we are delighted to share with you the latest accomplishments at Laser Photonics and reveal some strategic plans. This year, we have witnessed a growing awareness of the benefits of laser material processing from enterprises in a wide range of industries – to name a few, we have served clients operating in defense, nuclear power, oil and gas, nondestructive testing, robotics, and more. Along with this interest from industry professionals in our products, we have seen our stock rise significantly over the past months.
Internally, our commitment to continuously improve our technology, expand our sales and marketing efforts, and deliver outstanding shareholder returns remains vigorous.
Portfolio Expansion and Technological Advancements
Laser Photonics strives to make laser-powered technology accessible to small businesses and large enterprises that tackle the challenges of material processing. We have a robust portfolio of both stationery and handheld fiber laser systems for cleaning and surface conditioning, cutting, marking, and welding. Our product design and engineering teams stand ready to customize these systems according to our clients’ special requirements. LPC is also working to develop entry level laser cleaning models to increase access to our laser technology.
This year, we have upgraded our CleanTech cleaning and surface treatment products by integrating additional safety features, mobile connectivity, and automation. Our handheld laser cleaning systems are now more user-friendly, compact, mobile, and versatile than ever before. We are also increasing the output power of our Marlin portable line of laser systems for surface treatment in marine applications.
Further, LPC has enhanced its defense and military-oriented product line as we offer DefenseTech laser systems in collaboration with Fonon Technologies, our promotion sibling for defense and military applications. With new partnerships and increased sales in this division, this venture has proven its success and achieved a new level of monetization lately.
Expansion of Team and Facilities
We have been actively attracting new talents to expand our capabilities and accelerate efforts in sales and engineering. Among top management, LPC has welcomed a new Vice President of Sales, as well as new Directors for Semiconductor, Additive Manufacturing, and Outside Sales.
To accommodate our growing personnel and boost logistics and quality control, we are expanding to a new facility in Lake Mary, Fla. The new facility will also house LPC's state-of-the-art Customer Experience Center (CEC), where prospective clients will try out our advanced laser technology. A laser equipment training center for customers is also in the works. It will serve as a comprehensive educational hub for team leaders and individual users to receive hands-on practical guidance on the operation and maintenance of a laser system.
Marketing and Outreach
To expand our visibility and awareness in various industrial sectors and capital markets, we have actively participated in several key conferences this year, including NCMS technology showcases for government contractors, MegaRust 2024 in San Diego, focusing on corrosion solutions for the Navy, and many others.
In the near term, LPC is planning to attend the 2024 MINExpo International in Las Vegas and FABTECH 2024 in Orlando, Fla. We look forward to illustrating how our technology can improve mining and manufacturing operations and plant the seeds for new sales and partnerships. We would love to meet and connect with you there.
Further, LPC is continuing its successful multi-city Product Roadshows, bringing laser systems directly to customers for hands-on experience and interactive sessions. Each roadshow features product demos, panel discussions, marketing material distribution, Q&A sessions on industry trends, ESG benefits, and value propositions, helping prospective clients discover how LPC’s laser systems can meet their needs.
Strategic Plans and Diversification
With support from our parent company Fonon, an industrial laser equipment developer with four decades of expertise, we are throwing forces into the development of zero-width cutting technology for semiconductor materials, and the integration of AI into laser-powered robotic systems.
Together with Fonon, we have been advancing the development of the prototype for the Laser Shield Anti-Drone System (LSAD), a cutting-edge defense solution against unauthorized drones. Early tests at LPC’s Orlando R&D facility have been successful, marking a significant milestone for our teams.
Building on strategic pillars of sustainable laser material processing and superior customer value, we aim to increase our impact and scale up operations, diversify into new markets, and play a bigger role in both global and domestic regions. LPC will continue investing in product development, customer acquisition, and deepening our partnerships.
Reflecting on our recent accomplishments fills us with pride and excitement. Watching our community expand and our market capitalization increase reassures us that we are on the right track. Thank you for your unwavering support from Team Laser Photonics.
Regards,
Laser Photonics Corporation
About Laser Photonics Corporation
Laser Photonics is a vertically integrated manufacturer and R&D Center of Excellence for industrial laser technologies and systems. Laser Photonics seeks to disrupt the $46 billion, centuries-old sand and abrasives blasting markets, focusing on surface cleaning, rust removal, corrosion control, de-painting and other laser-based industrial
Venus Concept Announces Australian Regulatory Approval for Venus Bliss MAX
TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has clearance from the Therapeutic Goods Administration (TGA) in Australia to market the Venus Bliss MAX system. The Venus Bliss MAX is the Company’s flagship platform that offers a comprehensive, world-class solution for all customers’ body treatment needs and is currently available in select markets globally.
Featuring three of Venus Concept’s market leading technologies in one, the Venus Bliss MAX is a body shaping solution consisting of our proprietary (MP)2 applicator that combines Multi-Polar Radio Frequency with Pulsed Electro Magnetic Fields and advanced VariPulse™ technology for Cellulite Reduction and Skin treatments, Venus’ FlexMax EMS applicators for Muscle Conditioning and a diode laser for Fat Reduction treatments.
“We are excited to introduce to the Australian market the Venus Bliss MAX, our device that offers aesthetic clinicians an all-in-one body solution to customers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept. “The Venus Bliss Max continues to receive strong positive feedback globally from service providers of its complete body offering, and we are confident the same success will be replicated in Australia.”
Laser Photonics To Deliver DefenseTech Laser Cleaning Tool to Pearl Harbor Naval Shipyard & IMTF
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global developer of industrial laser systems for cleaning and other material processing applications, in partnership with its sibling company Fonon Technologies, announced today that it is processing the order for a DefenseTech laser system from the Pearl Harbor Naval Shipyard and Intermediate Maintenance Facility (PHNSY & IMF).
LPC is to deliver to PHNSY & IMF the DefenseTech MRLS Portable Finishing Laser 1010 (DTMF-1010) – an ultra-compact and portable pulsed fiber laser system for surface treatment. Designed explicitly for the naval tool kit, the DTMF-1010 is efficient in small-scale de-oxidation and rust control, top-layer coating removal and micro-surface polishing.
“Fonon Technologies is our trusted partner in promoting our laser-powered solutions to the U.S. Navy and defense maintenance professionals,” said Wayne Tupuola, CEO of LPC. “We developed the DTMF-1010 to make the surface treatment of naval assets near waterways a more sustainable process, and we are excited about this order from the Pearl Harbor Naval Shipyard.”
This order underscores the dedication of LPC and Fonon Technologies to equip naval bases, dry docks, boatyards and marinas with top-tier laser solutions and solidifies their reputation in the defense industry.
DefenseTech laser systems present a sustainable approach to surface preparation in defense and naval MRO settings, eliminating the need for toxic chemicals and abrasive media, thus reducing secondary waste and health risks for operators. DefenseTech systems efficiently remove corrosion, coatings, oil, wax, and residue while preserving the integrity of critical components, ensuring operational readiness and extending equipment lifespan.
For more information about Laser Photonics’ wide range of industrial laser solutions, visit https://www.laserphotonics.com/ or contact us at https://www.laserphotonics.com/contact. If interested in learning more about defense-based laser systems and the DefenseTech line of products, please visit https://fonon.us or contact Fonon Technologies’ sales department at sales@fonon.us.
About Laser Photonics Corporation
$DRMA = We been moving on up!
That is huge Boston! Do you own that Company? tia🥰
More very nice news! The webcast is at noon EST. I'm not gonna listen will wait for the transcript
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities
CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein
Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients Demonstrated Tumor Reduction Across V600 Mutation Types
CFT1946 Global Phase 1 Trial Continues to Enroll; Monotherapy and Combination Expansion Cohorts Advancing With Additional Data Expected in 2025
C4T To Host Webcast Today at 12:00 pm ET; Webcast Link Available Here
WATERTOWN, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced initial clinical data from the ongoing clinical trial of CFT1946, an orally bioavailable small molecule degrader of BRAF V600 mutations in solid tumors. These data, the first clinical results for a BRAF V600X degrader, were shared as a proffered paper in an oral presentation by Maria Vieito, M.D., MSc, medical oncologist at Vall d’Hebron University Hospital, Barcelona, Spain, at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13 – 17 in Barcelona, Spain.
“We are thrilled to share initial CFT1946 monotherapy data and highlight how this molecule, the first and only clinical-stage degrader of BRAF V600 mutants, may disrupt the current treatment landscape as it quickly progresses through clinical development,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “In addition to addressing the needs of patients with BRAF V600 mutant solid tumors, we believe these clinical data further reinforce the potential of our TORPEDO® platform to design innovative small molecule degraders that excite the medical community and have the potential to improve patients’ lives.”
“The data presented at the ESMO Congress 2024 are impressive given the early stage of development of CFT1946 and the novel modality,” said Dr. Vieito. “I am especially encouraged by the safety and tolerability of CFT1946, which may allow for additional monotherapy exploration as well as combination approaches to better understand how this oral degrader medicine may support the needs of patients refractory to BRAF inhibitor therapies.”
“We are pleased with the safety profile CFT1946 has demonstrated over a range of doses, as well as its pharmacokinetics, pharmacodynamics and initial anti-tumor activity. Taken together, these data support our hypothesis that degradation may offer a new therapeutic option over inhibition for BRAF V600 mutant solid tumors,” said Len Reyno, M.D., chief medical officer of C4 Therapeutics. “We are deeply appreciative of the contributions from patients, caregivers and the oncology community that have enabled us to deliver this preliminary monotherapy data and we look forward to continuing these important relationships as we progress CFT1946 toward additional milestones in 2025 and beyond.”
At the ESMO Congress 2024, C4T reported initial monotherapy data from the ongoing dose escalation Phase 1 clinical trial evaluating twice daily oral dosing of CFT1946, a degrader of BRAF V600 mutants, in patients with BRAF V600X solid tumors who have received at least one prior standard of care therapy for unresectable locally advanced or metastatic disease. Prior therapy must include a BRAF inhibitor, unless access is limited by regional regulatory approvals or reimbursement. As of the data cutoff date of July 19, 2024, a total of 36 patients received CFT1946 monotherapy across five dose escalation cohorts (20 mg BID, 80 mg BID, 160 mg BID, 320 mg BID and 640 mg BID). Patients received a median of three prior therapies; 35 patients (97 percent) had received prior BRAF inhibitor therapy. Thirty-three patients (92 percent) had a BRAF V600E mutation, two patients (six percent) had a BRAF V600K mutation and one patient (two percent) had a BRAF V600R mutation. Fourteen patients (39 percent) had melanoma, 14 patients (39 percent) had colorectal cancer, two patients (six percent) had non-small cell lung cancer and six patients (17 percent) had other cancers. All patients had unresectable, locally advanced or metastatic disease, and 32 patients (89 percent) entered the study with Stage IV cancer.
Safety and Tolerability: CFT1946 has a well-tolerated safety profile that supports further clinical development as monotherapy and in combination with MEK and EGFR inhibitors.
There were no dose-limiting toxicities and no treatment-related serious adverse events.
Adverse events occurring in more than 10 percent of patients were all Grade 1 or Grade 2.
No patients discontinued therapy or experienced treatment interruptions due to treatment-related adverse events.
No patients receiving CFT1946 monotherapy experienced a Grade 3 or higher treatment-related cutaneous adverse event. These cutaneous adverse events, which are related to BRAF wild-type inhibition, are commonly seen with BRAF inhibitors.
Pharmacokinetics (PK) and Pharmacodynamics (PD): Initial data demonstrating dose-dependent bioavailability and degradation of BRAF V600E protein support CFT1946 proof of mechanism.
CFT1946 exhibits dose-dependent bioavailability in the five dose levels explored to date.
In all available post-treatment biopsies collected to date, degradation of BRAF V600E protein is observed.
Anti-Tumor Activity: CFT1946 demonstrates evidence of monotherapy anti-tumor activity, supportive of early proof of degrader concept.
At data cutoff, 27 patients were evaluable for anti-tumor activity, which is measured by RECIST 1.1 criteria. 16 patients demonstrated reduction of target metastatic lesions.Two patients achieved a confirmed Partial Response.
Reduction of target lesion tumors was observed across histologies. Of the 27 patients evaluable for anti-tumor activity: Eleven patients had melanoma, eight of whom had evidence of tumor reduction. One patient with Stage IV BRAF V600K melanoma enrolled in the 320 mg BID cohort achieved a 67 percent decrease in target lesions as measured by RECIST 1.1 criteria. This patient remains on CFT1946 treatment and in response.Nine patients had colorectal cancer, three of whom had evidence of tumor reduction.Seven patients have other tumor histologies, three of whom had evidence of tumor reduction. One patient with Stage IV BRAF V600E pancreatic cancer, who has liver metastases, enrolled in the 640 mg BID cohort achieved a 55 percent decrease in target lesion as measured by RECIST 1.1 criteria. This patient remains on CFT1946 treatment and in response.
As of data cutoff, 11 of the patients who were evaluable for anti-tumor activity remain on therapy.
Next Steps and Future Milestones for CFT1946
The CFT1946 Phase 1 trial is ongoing and multiple indication-specific cohorts are advancing. Next steps and related milestones for CFT1946 include:
Complete Phase 1 monotherapy dose escalation – This portion of the trial is enrolling patients with BRAF V600X mutations across solid tumor indications. Patients are currently enrolling in the 640 mg BID PD backfill cohort as this dose level was recently declared safe. The full monotherapy dose escalation data are expected in 2025.
Complete expansion cohort exploring CFT1946 monotherapy in melanoma – This Phase 1 exploratory expansion cohort is evaluating the potential of CFT1946 monotherapy for melanoma patients refractory to BRAF inhibitor therapies. Enrollment for the 320 mg BID dose level is complete, and enrollment is ongoing for the 640 mg BID dose level. Data from these dose levels are expected in 2025.
Complete dose escalation cohort exploring CFT1946 in combination with cetuximab in colorectal cancer – This Phase 1b dose escalation cohort is enrolling patients at the 160 mg BID dose level to explore safety and tolerability, PK, PD and anti-tumor activity of CFT1946 in combination with cetuximab. These data are expected in 2025.
Initiate dose escalation cohort exploring CFT1946 in combination with trametinib in melanoma – This Phase 1b dose escalation cohort will explore safety and tolerability, PK, PD and anti-tumor activity of CFT1946 in combination with trametinib. C4T expects to initiate this cohort by year-end 2024.
C4T Webcast for Analysts and Investors
C4T will host an investor webcast today, September 13, 2024, at 12:00 pm ET. To join the webcast, please visit this link or the “Events & Presentations” page of the Investors section on the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived and available following the event.
About BRAF V600 Mutant Solid Tumors
BRAF mutations are found in approximately five percent of all cancers, including melanoma, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and other malignancies. Of these BRAF mutation cancer diagnoses, up to 90 percent contain an activating BRAF V600 mutation. BRAF V600 mutations are observed in up to 50 percent of patients with melanoma, nearly 10 percent of patients with CRC and approximately five percent of patients with NSCLC. Resistance to FDA-approved BRAF inhibitors results in median progression-free survival rates of less than 15 months across all indications.
About CFT1946
CFT1946 is an investigational, orally bioavailable small molecule degrader of BRAF V600 mutations in solid tumors currently being evaluated in a Phase 1/2 global clinical trial in patients refractory to BRAF inhibitors. CFT1946 is designed to be potent and selective against the BRAF V600 mutant form. Initial clinical data from the Phase 1 trial demonstrate that CFT1946 has a well-tolerated safety profile, demonstrates dose-dependent bioavailability and degradation of BRAF V600E protein, and demonstrates evidence of monotherapy anti-tumor activity. CFT1946 is the only degrader of BRAF V600 mutant solid tumors in clinical trials. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Geez Boston. I am sorry to hear this but there are many other fish in the sea!
Tenon Medical, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced the pricing of its "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of up to 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering"). The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $3.55 per share, will be exercisable immediately and will expire five years from the issuance date.
The closing of the Offering is expected to occur on or about September 16, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this Offering for commercial activity, working capital and general corporate purposes.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-281531) previously filed with the Securities and Exchange Commission ("SEC") which was declared effective on September 12, 2024. This Offering is being made only by means of a prospectus forming part of the effective registration statement. Copies of the preliminary prospectus and, when available, copies of the final prospectus, relating to the Offering may be obtained on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus relating to the Offering may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Tenon(R) Medical Announces the Introduction of the Catamaran(R) SE SI Joint Fusion System
~ New SI Joint Fixation Device Offers a 30% Reduction in Implant Size Providing Physicians Choices for Varying Anatomy and Treatment Strategies with the Catamaran Technology ~
~The SE System Can Also Be Utilized with a Manual Drilling Option During Implant Preparation~
LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced preparation for the initial alpha launch of the Company's new Catamaran SE SI Joint Fusion System targeted for the beginning of Q4. The Catamaran SE Fixation Device extends the line of implant offerings for physicians preferring a smaller Catamaran implant when performing a SI joint fusion procedure. The new implant offers a 30% reduction in implant width as compared to the original Catamaran fixation device, providing physicians options for smaller SI joint anatomy or revising previously treated SI joints with failed alternative SI joint implants where space is limited. The SE implant also comes with a hand drill option for those physicians who prefer to manually drill during implant preparation or do not have power sources readily available in their treating sites of care.
The alpha launch of the Catamaran SE will provide important initial user feedback from a select group of physician users to support a broader market launch in the coming months. This news of the Catamaran SE comes on the recent announcement by the Company of the Catamaran SI Joint Fusion System MAINSAIL Study's positive interim outcomes publication. Click here to view the publication in its entirety.
The Catamaran and Catamaran SE SI Joint Fixation devices are single robust fully MRI compatible titanium implants comprised of two pontoons, connected by an osteotome bridge, which is designed to transfix the SI joint along its longitudinal axis providing immediate fixation and stabilization of the joint, with the aim of achieving a successful long-term fusion. The Catamaran implant was developed with respect to AO principles of arthrodesis including 1) adequate joint preparation, 2) rigid fixation and stabilization, and 3) adequate bone graft augmentation. Via a minimally invasive inferior-posterior approach the Catamaran & Catamaran SE implant are delivered within the dense cortical bone of the sacrum and ilium, to transfix and stabilize the SI joint for the treatment of SIJ dysfunction. To date there have been over 700 Catamaran fixation devices implanted to treat primary SI Joint dysfunction and sacroiliitis, as well as revise previously treated SI joints with failed alterative SI joint implants.
Bryan Hoelzer, MD, Interventional Pain Physician and Medical Director of Southwest Spine and Pain Center, in Provo, UT., commented, "The clinical evidence validating the safety and efficacy of the inferior-posterior approach to treat SI Joint disease continues to grow with the recent Catamaran MAINSAIL Study publication. Continued advancement in implant technology as seen in the smaller Catamaran SE Fixation Device is exciting and will provide more improved options for myself and, my patients in treating and managing their painful SI joint disorders."and the entire interventional pain community."
Steven M. Foster, President and CEO of Tenon Medical, stated, "As a leader in the SI joint fusion market it is critical that we continually listen to input from our customers and respond with innovative technology that benefits their patients. The development and introduction of the Catamaran SE SI Joint Fusion System will provide our physician users with more choices to treat their patients with SI Joint disease. We look forward to a successful limited alpha launch and then move rapidly to a full market introduction."
About Tenon Medical, Inc.
Hi Dell. That is some great DD you did and I thank you for letting me know. I have never even bought this stock, I just reported the news but now I will be looking for dips to possibly take at least a small starters position. Hope you are doing well and please stay in touch :)😍
Hi Slim. LASE is a futuristic Company and IMHO should do well in the longer term. Today's news had no $ figure attached which suggests to me that it is not very much of a deal for them. LASE will need cash soon as they have a large cash burn rate and with the growth comes some pain. Once they announce a PP IMHO the shares tank back to $2.00 I just got lucky it was overbought!
$8 Mil from Biogen ain't no chicken scratch. I'm raising my long-term target from $18 to $22. I will welcome the Short maggotts that want to send this back to $4.00 and if they do I will be the 1st to buy. Enough said!
Laser Photonics Lands Sale With Acuren, Leader in Nondestructive Testing Services
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global developer of industrial laser systems for cleaning and other material processing applications, announced today that it has completed a sale and is working on a partnership agreement with the U.S. division of Acuren, a leading provider of asset protection services through nondestructive testing (NDT) and consulting.
LPC is to deliver its CleanTech Industrial Roughening Laser 3050 (CTIR-3050) to the U.S. Operations of Acuren in a sale that marks the beginning of the two companies’ relationship. The two companies are working together to have LPC join Acuren as a preferred partner for an ongoing purchasing program. This collaboration will provide Acuren with a smooth, expedited path for R&D and product customization processes, paving the way for the continued growth of both companies.
Acuren is one of the world’s largest inspection services companies, offering a wide range of NDT services through radiographic and ultrasonic testing, ground penetrating radar, infrared thermography and rope access technology (RAT). Acuren offers consulting engineering and lab testing services to enterprises in industry segments including chemical, nuclear power, pipeline, refinery, power generation, oil, automotive, aerospace, mining, manufacturing, renewable energy and pulp and paper.
“We are thrilled about working with Acuren – this order represents a major achievement for Laser Photonics as we venture into the nondestructive testing market,” said Wayne Tupuola, CEO of LPC. “Our laser surface treatment technology is a sustainable and efficient solution for corrosion removal and the protection of critical infrastructures.”
This sale strengthens LPC’s expanding presence in North America, increasing the brand’s recognizability amongst industry professionals and opening new business opportunities. The CTIR-3050 is LPC’s most powerful handheld laser system, offering top speed and efficiency for heavy-duty surface treatment applications.
For more information, visit Laser Photonics at https://laserphotonics.com/.
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr’s tumor targeting ability in humans.
MNPR-101 is Monopar’s proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase plasminogen activator receptor (uPAR). These include a majority of all triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.
A total-body positron emission tomography (PET) image was taken at 168 hours (7 days) post administration of MNPR-101-Zr (a zirconium-89 imaging radioisotope conjugated to MNPR-101) of the first cancer patient in the trial with one of the known high uPAR-expressing cancer types. The results, seen in Figure 1, demonstrate the specificity, durability, and uptake of MNPR-101-Zr in the metastatic tumors relative to normal tissue. The regions of higher uptake also align with the locations of the previously observed metastatic tumors on conventional FDG PET imaging.
https://ml.globenewswire.com/Resource/Download/cda29080-7e74-46b0-8b93-5925a209f2ab/2024-9-11-pr-figure-1-jpeg.jpg
“This is exactly what we had hoped to see – highly preferential uptake in the tumor,” said Andrew Cittadine, Monopar’s Chief Operating Officer.
MNPR-101-Zr was evaluated against FDG, the gold standard for detecting metastatic tumors. Figure 2 shows FDG uptake in its highest-uptake tumor compared to MNPR-101-Zr uptake in the same tumor imaged on the same Siemens Biograph Vision Quadra™ PET/CT scanner.
https://ml.globenewswire.com/Resource/Download/cb0b4c63-91dc-46e1-a3c5-862ccc4251d8/2024-9-11-pr-figure-2-jpeg.jpg
“At the Melbourne Theranostic Innovation Centre, we utilize one of the world's most sensitive PET/CT scanners. Using the same scanner for FDG and MNPR-101-Zr, the results show MNPR-101-Zr achieved uptake at sites of known disease with retention out to late points, which is promising for future therapeutic translation,” said Professor Rodney Hicks, MBBS(Hons), MD, FRACP, FICIS, FAAHMS, lead investigator on the MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial.
Monopar recently received clearance in Australia to initiate an MNPR-101-Lu Phase 1 therapeutic clinical trial [link] which is currently scheduled to launch in the fourth quarter of this calendar year.
“We are looking forward to sharing additional data at the upcoming European Association of Nuclear Medicine 2024 Annual Congress to be held in Hamburg, Germany on October 19-23, 2024, where our abstract has been accepted as a 'Top-Rated Oral Presentation' within the Scientific Program,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
Further information about the ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.
About Monopar Therapeutics Inc.
Monopar?Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include: the results show MNPR-101-Zr achieved uptake at sites of known disease with retention out to late points, which is promising for future therapeutic translation; and that an MNPR-101-Lu Phase 1 therapeutic clinic
On September 9, 2024, Tenon Medical, Inc. (the “Company”) received a letter from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) providing notification that the Company does not currently meet the minimum 500,000 publicly held shares requirement pursuant to Nasdaq Listing Rule 5550(a)(4) (the “Minimum Float Requirement”). As a result of the 1-for-8 reverse stock split of the Company’s common stock on September 6, 2024, the aggregate number of the Company’s outstanding shares of common stock was reduced from 4,081,767 shares on a pre-reverse-split basis to a total of 510,221 shares outstanding on a post-reverse split basis, with 490,364 of such shares currently qualifying as publicly held shares for purposes of the Minimum Float Requirement. The Staff has given us until October 24, 2024, to provide the Staff with a specific plan to regain compliance of the Minimum Float Requirement.
The Company expects to regain compliance with the Minimum Float Requirement in September through the consummation of a public offering of its common stock pursuant to its Registration Statement on Form S-1 (No. 333-281531), originally filed on August 14, 2024.
The Nasdaq notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market.
Currently, there are no PP and or offerings made public, you bring up an excellent point Moonboy because after checking the Q there is substantial cash burn and even if revenues increase as they say they will it won't be nearly enough to fund operations. So I think we'll see an offering within 1 month or two. I still love this Company's futuristic technology and my thinking is any new significant $$ order/contract will explode these shares. I still like anything under $4.00
Much more fun in the works. Stick around😆
Did I tell you yesterday that it was overbought and will come down HARD? In fact it came down so HARD that it got halted at $4.20
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor
OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature
Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population
No drug related discontinuations to date
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.
https://www.otcmarkets.com/stock/BCTX/news/story?e&id=2978177
$CNEY up 200% pre mkt. No news. At least I can't find any.
$HYSR new 52 weeks high 042
$LASE new 52 weeks high $9.36
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
Milestone Results in $8 Million Payment to C4 Therapeutics
WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has successfully delivered a second development candidate to Biogen and earned an $8 million milestone payment. This marks the final development candidate under this strategic collaboration.
“We are thrilled to deliver a highly catalytic, brain penetrant orally bioavailable BiDAC™ degrader development candidate to Biogen in their pursuit of discovering, developing and delivering innovative therapies that improve the lives of patients,” said Andrew Hirsch, president and chief executive officer. “It is rare that discovery collaborations deliver one, much less two, development candidates to the partner. This result is a testament to the dedication of the Biogen and C4T teams and the productivity of our TORPEDO® platform, which has demonstrated its potential to design innovative degraders against a broad range of target classes. Since our founding in 2015, we have discovered and advanced four development candidates for our clinical pipeline and delivered two development candidates to Biogen, an impressive feat for a company of our size. We are proud to continue advancing the exciting field of targeted protein degradation and bring new medicines to patients.”
Under the terms of the strategic collaboration established in 2018, C4T provided expertise and research services in targeted protein degradation and Biogen provided scientific and drug development capabilities. Biogen is responsible for all future clinical development and commercialization for development candidates delivered under the collaboration. Previously, C4T earned an $8 million payment in April 2024 after Biogen accepted delivery of a first development candidate in an undisclosed indication as part of this collaboration.
It's overbought. I am now out of 3/4 of my holdings. Just holding the rest just in case they keep pumping. IMHO when she comes down it will be a hard drop.
Laser Photonics Shares Concept Animation of Next-Gen CleanTech Robotic Cell
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global industrial developer of laser systems for cleaning and other material processing applications, unveils the visual concept of its next-generation CleanTech Industrial Robotic Cell 6040 (CTIR-6040), in response to the increasing focus on worker safety in industrial operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910646258/en/
Increasingly, enterprises in the industrial sector view worker safety not only as their moral and legal obligation but also as a strategic business decision. Driven by this prioritization of safety, as well as by labor shortages, technological advancements, and the need for customization tools, the robot cell market has been surging. The value of this market is forecast to reach $12.8 billion by 2034 from its 2024 value of $3.5 billion, growing at a CAGR of 14.6%, according to an April 2024 analysis by Fact.MR.
LPC is one of the innovators driving this shift toward industrial automation. Nearly a year ago, the company revealed its first CleanTech Robotic Cell, which combined advanced laser technology with human-operated robotics inside the enclosed workcell. Now, LPC carries its next-generation CTIR-6040, equipped with additional safety measures, mobile connectivity, and new customization features.
“Our team at Laser Photonics is elevating the bar for safe, repeatable, and precise laser cleaning,” said Wayne Tupuola, CEO of LPC. “We are one of the first to equip the robotic arm with laser cleaning capabilities, and we have continued to advance this technology to stay ahead of the curve and expand our technological lead and market opportunities.”
The CTIR-6040 comes with a custom workcell best suited to the needs of the client. Configurations include Class IV or Class I safety enclosure, fume extractor installation, variable laser system integration, flexible programming, and more. LPC invites its community to view the visual concept of the CTIR-6040 on its corporate website.
For more information about the CleanTech line of laser cleaning systems, please visit https://www.laserphotonics.com or contact our sales department at fiberlaser@laserphotonics.com.
Yes, I agree. If it should drop under $4.00 then IMHO it's a strong buy. These guys post job openings on Linkedin so my feeling is they have contracts in the hopper.
Amazingly, and I do not know why, but the shares got crushed during the pre-market hours down to $3.99! I was like what the Fluck? I read the news several times and there was not one thing negative, not a word it was nice news. Anyway, I bought 10k shares @ $4.20 and unless I have dementia I feel it was taking candy from a baby.
This is one very schizophrenic stock but I'm keeping my $18.00 long term target
I love it!